Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin

Cancer Research

Volumn 58, Issue 7, 1998, Pages 1538-1543

  Ruan, Sanbao ^a   Okcu, M Fatih ^a   Ren, Jiang Ping ^a   Chiao, Paul ^a   Andreeff, Michael ^a   Levin, Victor ^a   Zhang, Wei ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CHEMOSENSITIVITY; GLIOBLASTOMA; GROWTH REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CELL DEATH; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DOXORUBICIN; DOXYCYCLINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032054738     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ringertz, N. "Grading" of gliomas. Acta Pathol. Microbiol. Scand., 27: 51-64, 1950.
2. Friedman, H. S., Colvin, O. M., Skapek, S. X., Ludeman, S. M., Elion, G. B., Schold, S. C., Jacobsen, P. F., Muhlbaier, L. H., and Bigner, D. D. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res., 48: 4189-4195, 1988.
3. Steward, D. J. The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat. Rev., 16: 129-160, 1989.
4. Conrad, C. A., Milosavlijevic, V. P., and Yung, W. K. A. Advances in chemotherapy for adult primary brain tumors. Neurosurg. Clin. North Am., 13: 795-812, 1995.
5. Sherr, C. J. Mammalian G1 cyclins. Cell, 73: 1059-1065, 1993.
6. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
7. Zhang, H., Xiong, Y., and Beach, D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Cell. Biol., 4: 897-906, 1993.
8. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
9. Harper, J. W., Adami, G. R., Wei, N., Keuomarsi, K., and Elledge, S. J. The WAF1/Cip1 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
10. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90-98, 1994.
11. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
12. Zhang, W. Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travail, S., Deisseroth, A. B., and Mercer, W. E. p53-independent induction of WAF1/Cip1 in human leukemia cells is correlated with growth arrest accompanying monocyte/ macrophage differentiation. Cancer Res., 55: 668-674, 1995.
13. Jung, J. M., Li, H., Kobayashi, T., Kyritsis, A., Bruner, J., Langford, L., Levin, V., and Zhang, W. The inhibition of human glioblastoma cell growth by WAF1/Cip1 can be attenuated by mutant p53. Cell Growth Diff., 6: 909-913, 1995.
14. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The WAF1/Cip1 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574-577, 1994.
15. Umar, A., Buermeyer, A. B., Simon, J. A., Thomas, D. C., Clark, A. B., Liskay, R. M., and Kunkel, T. A. Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis. Cell, 87: 65-73, 1996.
16. Zhang, W., Kornblau, S. M., Kobayashi, T., Gambel, A., McClain, C. D., Claxton, D., and Deisseroth, A. B. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res., 1: 1051-1057, 1995.
17. WAF1/Cip1 in human brain tumors. Oncogene, 11: 2021-2028, 1995.
18. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking WAF1/Cip1. Nature (Lond.), 381: 713-716, 1996.
19. McDonald, E. R., Wu, G. S., Waldman, T., and El-Deiry, W. S. Repair defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res., 56: 2250-2255, 1996.
20. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
21. Kobayashi, T., Consoli, U., Andreeff, M., Shiku, H., Deisseroth, A. B., and Zhang, W. Activation of WAF1/Cip1 by a temperature sensitive mutant of human p53 does not lead to apoptosis. Oncogene, 11: 2311-2316, 1995.
22. Gorospe, M., Cirielli, C., Wang, X., Seth, P., Capogrossi, M. C., and Holbrook, N. J. p21 (Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene, 14: 929-935, 1997.
23. Gorospe, M., Wang, X., Guyton, K. Z., and Holbrook, N. J. Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol. Cell. Biol., 16: 6654-6660, 1996.
24. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Jillen, W., and Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. Science (Washington DC), 268: 1766-1769, 1995.
25. von Deimling, A., Eibi, R. H., Ohgaki, H., Louis, D. N., von Ammon, K., Peterson, I., Kleihues, P., Chung, R. Y., Wiestler, O. D., and Seizinger, B. R. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res., 52: 2987-2990, 1992.
26. Van Meir, E. C., Kikuchi, U., Tada, M., Li, H., Diserens, A-C., Wojcik, B. E., Huang, H-J. S., Friedmann, T., de Tribolet, N., and Cavenee, W. K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res., 54: 649-652, 1994.
27. Srivenugopal, K. S., and Ali-Osman F. Stimulation and inhibition of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced strand breaks and interstrand cross-linking in Col E1 plasmid deoxyribonucleic acid by polyamines and inorganic cations. Biochem. Pharmacol., 40: 473-479, 1990.
28. Gralla, J. D., Dwight, S. S., and Poljak, L G. Formation of blocking lesions in identical DNA sequences by the nitrosourea and platinum classes of anticancer drugs. Cancer Res., 47: 5092-5096, 1987.
29. 6-alkylguanine-DNA alkyltransfcrase. Br. J. Cancer, 75: 500-505, 1997.
30. Hunter, K. J., Deen, D. F., Pellarin, M., and Marton, L. J. Effect of α-difluoro-methylornithine on 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloro-platinum(II) cytotoxicity, DNA interstrand cross-linking, and growth in human brain tumor cell lines in vitro. Cancer Res., 50: 2769-2772, 1990.
31. WAF1 is required for survival of differentiating neuroblastoma cells. Mol. Cell. Biol., 16: 1335-1341, 1996.
32. Wang J., and Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science (Washington DC), 273: 359-361, 1996.
33. 6 benzylguanine analogues on sensitivity of human tumor cells to the cytoxic effects of alkylating agents. Cancer Res., 51: 3367-3372, 1991.
34. Perkins, N. D. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science (Washington DC), 275: 523-527, 1997.
35. Waf1/cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. Oncogene, 14: 1875-1882, 1997.
36. Li, R., Waga, S., Hannon, G. J., Beech, D., and Stillman, B. Differential effects by the WAF1/Cip1 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature (Lond.), 371: 534-537, 1994.
37. Shivji, M. K. K., Grey, S. J., Strausfeld, U. P., Wood, R. D., and Blow, J. J. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. Curr. Biol., 12: 1062-1068 1994.
38. Pan, Z-Q., Reardon, J. T., Li, L., Flores-Roas, H., Legerski, R., Sancar, A., and Hurwitz, J. Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J. Biol. Chem., 270: 22008-22016, 1995.
39. Kyritsis, T., Bondy, M. L., Hess, K. R., Cunningham, J. E., Zhu, D., Amos, C. J., Yung, W. K. A., Levin, V. A., and Bruner, J. M. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin. Cancer Res., 1: 1617-1622, 1995.
40. Fan, S-J., Smith, M. L., Rivet, D. J., II, Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
41. Consoli, U., Li, H., Huang, P., Kobayashi, T., Andreeff, M., Levin, V., and Zhang, W. Enhancement of apoptosis in irradiated glioblastoma cells by pentoxifylline. Oncol. Rep., 4: 673-678, 1997.